武清区龙济包皮多少钱(武清区龙济男科医院的电话) (今日更新中)

BEIJING, Sept. 27 (Xinhuanet) -- Scientists have been making great efforts to show how harmful coffee is to us, though no evidence yet. A latest study may be reassuring for coffee-lovers.Women who drink caffeinated coffee are less likely to be depressed than those don't. And the more they drink, the lower risk of developing depression, according to a study published Monday in the Archives of Internal Medicine. Researchers of the study tracked the health of over 50,000 women aged between 30 and 55 in 1996 for a decade and recorded their mental health and coffee intake periodically.They find that women who drank two or three cups of coffee per day were 15 percent less likely than those who drank little or decaffeinated coffee to be depressed.And for those who drank four or more cups, the risk of developing depression reduced by 20 percent.The reason why coffee could protect depression is not clear. But the scientists from the Harvard University speculated that caffeine was the key player. More research is needed to show whether caffeine can ward off depression.It might be that not-depressed people tended to be more activated and the habit of coffee drinking just fit in their lifestyle.However, the depressed ones, who might suffer from sleeplessness, chose not to drink coffee because the caffeine might exacerbate it."There's no need to start drinking coffee," said Dr. Alberto Ascherio, the senior author of the study, "The message is that coffee is safe to drink, with no adverse effects. That's really all that can be said."

JIUQUAN, Gansu, Sept. 26 (Xinhua) -- Engineers are conducting the final preparations before launching China's first space laboratory module at the end of this week at a launch center in northwest China.The unmanned Tiangong-1 module was originally scheduled to be launched into low Earth orbit between Sept. 27 and 30. However, a weather forecast showing the arrival of a cold air mass at the Jiuquan Satellite Launch Center forced the launch to be rescheduled for Sept. 29 or 30, depending on weather and other factors."This is a significant test. We've never done such a thing before," said Lu Jinrong, the launch center's chief engineer.A full ground simulation was conducted on Sunday afternoon to ensure that the module and its Long March 2F carrier rocket are prepared for the actual launch.Cui Jijun, commander-in-chief of the launch site system and director of Jiuquan Satellite Launch Center, told Xinhua that they developed a new target spacecraft for the mission and made more than 170 technical improvements to the Long March 2F, China's manned orbital carrier rocket.Engineers have also made more than 100 updates at the launch site in order to make it compatible with the Tiangong-1, Cui added.The module will conduct docking experiments after entering orbit, which is the first step in China's space station program.Cui said the launch site has an updated computer center and command monitoring system and increased ability to adapt to changes in mission conditions, as well as the resources to handle both the launch and command duties. An integrated simulation training system for space launching has also been developed for the docking mission.The mission comes just one month after the Long March 2C rocket malfunctioned and failed to send an experimental satellite into orbit. The Tiangong-1 mission was subsequently rescheduled in order to allow engineers to sort out any problems that might occur during the launch.Cui said that engineers conducted a two-month comprehensive technical check on equipment at the launch site from March to May. The safety and reliability of all the instruments have been significantly improved."[The launch site] has the full conditions to conduct the Tiangong-1 mission," said Cui.The Tiangong-1 will remain in orbit for two years. During its mission, it will dock with China's Shenzhou-8, -9 and -10 spacecrafts.Unmanned docking procedures will be an essential step toward China achieving its goal of establishing a manned space station around 2020.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

KIEV, Aug. 2 (Xinhua) -- Ukraine's regional health authority declared Tuesday a cholera epidemic in the eastern region of Donetsk had ended.All 26 people who had been treated for the disease had been discharged from hospital, the press-service of the Donetsk Regional Sanitary and Epidemiological Service said on its official website.As of this week, no new cases had been registered, the statement said.The cholera outbreak hit eastern Ukraine in late May. The disease can cause rapid dehydration and death.The outbreak was believed to be associated with fish and drinking water supplies from the Sea of Azov.

来源：资阳报